Stocks and Investing Stocks and Investing
Thu, April 23, 2020

Matthew Harrison Maintained (BIIB) at Sell with Decreased Target to $301 on, Apr 23rd, 2020


Published on 2024-10-27 03:50:33 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Sell with Decreased Target from $302 to $301 on, Apr 23rd, 2020.

Matthew has made no other calls on BIIB in the last 4 months.



There are 7 other peers that have a rating on BIIB. Out of the 7 peers that are also analyzing BIIB, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Salim Syed of "Mizuho" Maintained at Hold with Increased Target to $316 on, Tuesday, February 25th, 2020
  • Mohit Bansal of "Wells Fargo" Maintained at Hold with Increased Target to $311 on, Thursday, February 6th, 2020
  • Alethia Young of "Cantor Fitzgerald" Reiterated at Hold with Increased Target to $361 on, Thursday, February 6th, 2020


These are the ratings of the 4 analyists that currently disagree with Matthew


  • Christopher Marai of "Nomura" Maintained at Strong Buy with Increased Target to $392 on, Friday, February 7th, 2020
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $410 on, Thursday, February 6th, 2020
  • Brian Skorney of "Baird" Maintained at Sell with Increased Target to $290 on, Thursday, February 6th, 2020
  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy and Held Target at $360 on, Monday, January 27th, 2020
Contributing Sources